1. Fala L. Xiaflex (Collagenase ClostridiumHistolyticum), First Drug Approved by the FDA for Peyronie’s Disease. American Health & Drug Benefits. 2014 March; 7: p. Special Feature.
2. European Medicines Agency. Xiapex (collagenase Clostridium histolyticum): summary of product characteristics. Available from: http://www.ea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002048/WC500103373.pdf.
3. Auxilium Pharmaceuticals. Xiaflex (collagenase Clostridium histolyticum): US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf [accessed 19.07.17].
4. Humoral immune responses in Peyronie’s disease patients receiving clostridial collagenase therapy;Hamilton;J Urol,1986
5. Collagenase for Peyronie’s disease experimental studies;Gelbard;Urol Res,1982